Lori Kunkel

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 655 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Michael B. Atkins, Lori Kunkel, Mario Sznol et al. · PubMed · 2000 · 518 citations

Medicine, Immunology, Oncology +11

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

John C. Byrd, Timothy J. Murphy, Robin Howard et al. · Journal of Clinical Oncology · 2001 · 511 citations

Pharmacy, Oncology, Pharmacokinetics +15

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Julie M. Vose, Brian K. Link, Michael L. Grossbard et al. · Journal of Clinical Oncology · 2001 · 416 citations

Medicine, Oncology, Pharmacotherapy +15